MTmedical Institute of Health

MTmedical Institute of Health was a biotechnology company primarily focused on the clinical development of 4-methylumbelliferone (also known as hymecromone or Heparvit) for the treatment of chronic viral hepatitis. The company sponsored a Phase 2 clinical trial to evaluate the drug's potential in reducing viral load and improving liver function in patients with chronic hepatitis B (HBV) and hepatitis C (HCV). This research was conducted in collaboration with the University of Texas Health Science Center at San Antonio and BioMonde Preparations Limited. The company's therapeutic approach targeted the inhibition of hyaluronan synthesis to mitigate liver inflammation and fibrosis. MTmedical Institute of Health appears to have been a small, research-focused entity that has been inactive since the mid-2000s.